PRECISION

Principal Investigator:
Rao Gudipati, MD (MCVI)

Sub-Investigators:
Peter Fattal, MD                John Collins, MD
Safwan kassas, MD            David Chen, MD
William Felten, MD            Shiraz Shariff, MD
Sarosh Anwar, MD            Gregory Pellizzon, MD
Jeffery Carney, MD            Alok Maheshwari, MD
Susan Sallach, MD             Joyce Geary, MD

Sponsor:
Pfizer

Study Purpose:
Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen Or Naproxen; A Randomized, Double Blind, Parallel-Group Study Of Cardiovascular Safety In Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing Celecoxib With Naproxen and Ibuprofen.

Objective:
To assess the effect of celecoxib when compared to traditional (non-selective) nonsteriodal anti-inflammatory drugs (NSAIDs) on cardiovascular events, gastrointestinal events, renal events and symptomatic benefit in subjects with osteoarthritis (OA) or rheumatoid arthritis (RA) with cardiovascular disease (CVD) or at high risk for developing CVD.

Status:
Active enrollment

If you have any questions, please feel free to contact the coordinators, and they will be happy to answer any questions you have regarding this study.

<< Back